Optomed USA is proud to announce the launch of its latest innovation: Optomed Lumo, a next-generation handheld fundus camera designed to bring high-quality retinal imaging into primary care and beyond.
Optomed Lumo is a non-mydriatic fundus camera cleared under the FDA PJZ product code, intended to capture and store images of the eye. With wireless DICOM integration, programmable workflows, and intuitive user guidance, Optomed Lumo is engineered for flexibility and ease of use in a variety of healthcare settings.
“Optomed Lumo represents a major step toward our mission of making retinal imaging more accessible. By combining mobility, usability, and seamless integration, we’re helping clinicians bring eye imaging to patients wherever they are — whether in a clinic, community center, or remote care setting.” said David Frasch, managing director of Optomed USA.
The growth of Oculomics, the study of systemic health signals observable in the retina, is driving demand for greater access to high-quality retinal imaging. Optomed is meeting this need by expanding the availability of tools like the Optomed Lumo, which enables primary care providers, community clinics, and mobile health programs to capture retinal images in regions where access to imaging has traditionally been limited.
“We designed Optomed Lumo in close collaboration with healthcare professionals to meet the real-world needs of today’s care environments. Its intuitive interface, dual form factor, and connectivity features make it easy to adopt.” said Laura Piila, vice president of Devices at Optomed. “Optomed Lumo’s versatility as both a handheld and desktop device makes it an ideal fit for any care environment.”
Optomed Lumo is now available in the United States. For more information, visit www.optomed.com/us/optomedlumo
About Optomed
Optomed USA, Inc. is a wholly owned subsidiary of Optomed Plc, a Finnish medical technology company and one of the leading providers of handheld fundus cameras worldwide. Optomed Plc combines handheld screening devices with software and optional artificial intelligence integration with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy.
In its business, Optomed Plc focuses on eye-screening devices and software solutions-related R&D in Finland, and sales through different channels in over 60 countries.